A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Huntington’s disease (HD).

Condition studied

Huntington’s disease (HD).

Investigational medicinal product(s)

Every trial of Pridopidine across our registers →

Eligibility

Primary endpoint

1. Change from baseline to Week 52 in cUHDRS.

Endpoint detail

1. Change from baseline to Week 52 in functional capacity as measured by the Total Functional Capacity (TFC) score., 2. Change from baseline to Week 52 in motor function as measured by Quantitative Motor (Q-Motor) Finger Tapping Inter-onset Interval (FT-IOI) mean (Digitomotography)., 3. Change from baseline to Week 52 in cognition as measured by Stroop Word Reading (SWR)., 4. Incidence (count and rate) and nature of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) overall, by severity, by relationship to study drug, and those that led to discontinuation of study drug and/or withdrawal from the study.